Forsta AP Fonden lowered its position in shares of Danaher Co. (NYSE:DHR) by 4.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 406,958 shares of the conglomerate’s stock after selling 18,000 shares during the quarter. Danaher makes up about 1.4% of Forsta AP Fonden’s investment portfolio, making the stock its 18th largest position. Forsta AP Fonden’s holdings in Danaher were worth $37,774,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in DHR. GQG Partners LLC bought a new stake in shares of Danaher during the second quarter worth $101,000. Zions Bancorporation raised its position in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after acquiring an additional 667 shares during the last quarter. Patten Group Inc. raised its position in shares of Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 3,497 shares during the last quarter. First Personal Financial Services raised its position in shares of Danaher by 128.9% during the fourth quarter. First Personal Financial Services now owns 1,227 shares of the conglomerate’s stock worth $114,000 after acquiring an additional 691 shares during the last quarter. Finally, Calton & Associates Inc. bought a new stake in shares of Danaher during the fourth quarter worth $114,000. Institutional investors own 75.88% of the company’s stock.

Shares of Danaher Co. (NYSE:DHR) opened at $94.98 on Wednesday. The company has a market capitalization of $66,462.61, a PE ratio of 23.67, a P/E/G ratio of 2.01 and a beta of 1.04. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $104.82.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the company earned $1.05 earnings per share. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. equities analysts expect that Danaher Co. will post 4.37 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were issued a $0.14 dividend. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.59%. Danaher’s dividend payout ratio (DPR) is currently 15.86%.

DHR has been the subject of a number of recent research reports. Credit Suisse Group restated a “hold” rating and set a $99.00 target price on shares of Danaher in a research report on Tuesday, December 19th. Zacks Investment Research downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Robert W. Baird restated a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Royal Bank of Canada reiterated a “hold” rating and issued a $96.00 price objective on shares of Danaher in a report on Thursday, January 4th. Finally, Morgan Stanley upped their price objective on Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $100.13.

In other Danaher news, CFO Daniel L. Comas sold 62,989 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $101.96, for a total value of $6,422,358.44. Following the completion of the sale, the chief financial officer now directly owns 227,805 shares in the company, valued at $23,226,997.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $102.29, for a total value of $4,397,242.52. Following the transaction, the senior vice president now directly owns 82,008 shares of the company’s stock, valued at $8,388,598.32. The disclosure for this sale can be found here. Insiders sold 274,913 shares of company stock valued at $27,729,293 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.

WARNING: This report was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://theolympiareport.com/2018/02/14/forsta-ap-fonden-sells-18000-shares-of-danaher-co-dhr.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.